Clinical Trial Update: Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) [Phase 2]

View source ↗

Summary

A Phase 2 trial of incobotulinum toxin A for sialorrhea in Parkinson disease and amyotrophic lateral sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis
• Parkinson Disease

Drugs mentioned

• Incobotulinum Toxin A (incobotulinum toxin A)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Parkinson Disease, Amyotrophic Lateral Sclerosis | Phase 2 | Status: WITHDRAWN